why Astrazeneca plc ADR [AZN] is a Good Choice for Investors After New Price Target of $81.96

Astrazeneca plc ADR [NASDAQ: AZN] loss -0.76% on the last trading session, reaching $65.14 price per share at the time. The company report on February 5, 2024 at 9:00 AM that Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach.

Yiviva and AstraZeneca Strategic Collaboration Memorandum Signing Ceremony.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

If compared to the average trading volume of 5.43M shares, AZN reached a trading volume of 10793662 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here is what top equities market gurus are saying about Astrazeneca plc ADR [AZN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AZN shares is $81.96 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AZN stock is a recommendation set at 1.52. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Astrazeneca plc ADR shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 23, 2024.

The Average True Range (ATR) for Astrazeneca plc ADR is set at 0.94, with the Price to Sales ratio for AZN stock in the period of the last 12 months amounting to 4.49. The Price to Book ratio for the last quarter was 5.43, with the Price to Cash per share for the same quarter was set at 1.65. Price to Free Cash Flow for AZN in the course of the last twelve months was 21.49 with Quick ratio for the last quarter at 0.60.

Trading performance analysis for AZN stock

Astrazeneca plc ADR [AZN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.05. With this latest performance, AZN shares dropped by -5.29% in over the last four-week period, additionally sinking by -6.14% over the last 6 months – not to mention a rise of 3.15% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AZN stock in for the last two-week period is set at 36.88, with the RSI for the last a single of trading hit 28.44, and the three-weeks RSI is set at 42.10 for Astrazeneca plc ADR [AZN]. The present Moving Average for the last 50 days of trading for this stock 66.22, while it was recorded at 66.29 for the last single week of trading, and 68.52 for the last 200 days.

Astrazeneca plc ADR [AZN]: A deeper dive into fundamental analysis

Astrazeneca plc ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.79.

Astrazeneca plc ADR [AZN]: An earnings per share (EPS) analysis

With the latest financial reports released by the company, Astrazeneca plc ADR posted 0.69/share EPS, while the average EPS was predicted by analysts to be reported at 0.67/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 3.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AZN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Astrazeneca plc ADR go to 13.10%.

An analysis of Institutional ownership at Astrazeneca plc ADR [AZN]

The top three institutional holders of AZN stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in AZN stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in AZN stock with ownership which is approximately 5.8325%.